Research progress in the preoperative radiotherapy and immunotherapy for primary liver cancer / 中华放射医学与防护杂志

Liver cancer is one of the most common cancers in China. In recent years, liver cancer tends to be treated with comprehensive therapies, including surgery, ablation, interventional embolization, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and liver transplantation. At present, the low surgical resectionrate is one of the main factors affecting the prognosis of liver cancer patients. Preoperative neoadjuvant therapy or conversion therapy for liver cancer can maximize the rate of surgical resection and improve the prognosis. With the rapid development of radiotherapy and immunotherapy in the comprehensive treatment of liver cancer, it has been gradually confirmed that the unique effects of preoperative radiotherapy and immune therapy for liver cancer can improve the prognosis of the patients. Therefore, this paper reviewed the research progress in the preoperative radiotherapy and immunotherapy for liver cancer by searching relevant literature and reports at home and abroad.

Therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer / 临床肝胆病杂志

ObjectiveTo investigate the clinical therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer. MethodsA total of 122 previously untreated patients with locally advanced pancreatic cancer who were not able to undergo surgical resection and were admitted to Fuzhou General Hospital from June 2008 to June 2013 were selected, and according to the therapies, they were divided into the group with a combination of gemcitabine hydrochloride and stereotactic radiotherapy (group A, n=56) and the group with gemcitabine therapy alone (group B, n=66). The changes in condition, toxic and side effects, and death time were recorded. The chi-square test was applied for comparison between groups, and the Kaplan-Meier method was applied for plotting survival curves. ResultsThere was a significant difference in response rate between group A and group B ［67.8% (38/56) vs 227% (15/66), χ2=25.11, P＜0.01］; the effective pain-relieving rate showed a significant difference between group A and group B (95.8% vs 77.2%, χ2=7.39, P＜0.01); there were significant differences in 1-year survival rate, 2-year survival rate, and median survival time between the two groups ［58.9% (33/56) vs 31.8% (21/66), χ2=9.03, P＜0.01; 28.6% (16/56) vs 106% (7/66), χ2=6.39, P＜0.01; 12.8 months vs 7.9 months; χ2=15.51, P＜0.01］. ConclusionGemcitabine hydrochloride combined with stereotactic radiotherapy has good short- and long-term efficacy, and toxic and side effects are tolerable.